Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLCs registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Watson/Genelabs Prestara "approvable"

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Genelabs will conduct six-month clinical trial to confirm a positive effect for Prestara (prasterone, formerly Aslera) with bone mineral density as the primary endpoint, following an Aug. 28 "approvable" letter. Genelabs' study GL95-02 showed an effect on bone mineral density in 381 women with mild to moderate systemic lupus erythematosus; the other pivotal trial used steroid reduction as the endpoint. FDA's Arthritis Advisory Committee had expressed concern about prasterone's failure to reach prospectively defined primary endpoints at its April 19, 2001 meeting, and FDA issued a "not approvable" letter June 26, 2001. Additional analyses from GL95-02 were submitted in February 2002, showing significant increases in lumbar spine and hip bone mineral densit
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS002036

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel